Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amlodipine
Drug ID BADD_D00121
Description Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers [A175327]. Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure [A175321]. The option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label].
Indications and Usage For the treatment of hypertension and chronic stable angina.
Marketing Status Prescription; Discontinued
ATC Code C08CA01
DrugBank ID DB00381
KEGG ID D07450
MeSH ID D017311
PubChem ID 2162
TTD Drug ID D08JIV
NDC Product Code 52652-5001; 46287-035
Synonyms Amlodipine | Amlodipine, (+-)-Isomer | Amlodipine Besylate | Amlodipine, (+-)-Isomer, Maleate (1:1) | Amlodipine, (S)-Isomer, Maleate (1:1) | Amlodis | Astudal | Norvasc | Istin | Amlor | Amlodipine Maleate | Amlodipine Maleate (1:1) | Amlodipine, (R)-Isomer
Chemical Information
Molecular Formula C20H25ClN2O5
CAS Registry Number 88150-42-9
SMILES CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Extrasystoles02.03.02.003--Not Available
Eye disorder06.08.03.001--Not Available
Eye haemorrhage24.07.05.002; 06.07.02.0010.000046%Not Available
Eye pain06.08.03.0020.000046%
Eyelid oedema10.01.05.001; 06.04.04.004; 23.04.01.0030.000077%Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.000092%
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Feeling hot08.01.09.0090.000061%Not Available
Femur fracture15.08.03.003; 12.04.01.003--Not Available
Flat affect19.04.01.004--Not Available
Flatulence07.01.04.0020.000077%
Fluid retention14.05.06.002; 20.01.02.0030.000061%Not Available
Flushing08.01.03.025; 24.03.01.002; 23.06.05.0030.000153%
Gait disturbance17.02.05.016; 08.01.02.0020.000184%
Gamma-glutamyltransferase increased13.03.01.0110.000031%
Gastric cancer16.13.03.001; 07.21.02.0010.000008%Not Available
Gastric polyps07.20.01.003; 16.05.03.0010.000031%Not Available
Gastric ulcer07.04.03.0020.000046%
Gastric ulcer haemorrhage07.04.03.005; 24.07.02.0030.000031%Not Available
Gastritis07.08.02.0010.000046%
Gastritis erosive07.04.03.0030.000061%Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.0040.000046%
Gingival bleeding07.09.07.001; 24.07.02.0100.000061%Not Available
Gingival disorder07.09.03.0010.000031%Not Available
Gingival hyperplasia07.09.03.0020.000061%Not Available
Gingival hypertrophy07.09.03.0060.000092%Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 17 Pages